Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04959097 · ClinicalTrials.gov registry record

RB Liquid Biopsy Biorepository

A clinical trial of Retinoblastoma and Retinoblastoma Bilateral, sponsored by Children's Hospital Los Angeles.

Recruiting
Registry status
800
Enrollment target
1
Study location

NCT04959097 is a study of Retinoblastoma and Retinoblastoma Bilateral that is actively recruiting participants, run by Children's Hospital Los Angeles. The registered enrollment target is 800 participants, above the 539-participant average among 15 other Retinoblastoma trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04959097, a study of Retinoblastoma and Retinoblastoma Bilateral, is actively recruiting participants, sponsored by Children's Hospital Los Angeles.

RECRUITING
Registry status
800 participants
Enrollment target
1
Study location

Study Summary

Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.

Study Locations (1)

California

  • Children's Hospital Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2017-01-01
Est. Completion 2030-12-31

Sponsor

Children's Hospital Los Angeles

119 total trials

What the Registry Record Tells You About NCT04959097

The ClinicalTrials.gov registry entry for NCT04959097 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 539-participant average among 15 other Retinoblastoma trials with a reported enrollment target (48% higher). The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Retinoblastoma appearing as the primary indexed condition, and to 0 interventions.

NCT04959097 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04959097 about?

NCT04959097 is a clinical study titled "RB Liquid Biopsy Biorepository". Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front o...

What is the current status of trial NCT04959097?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2017-01-01. Estimated completion is 2030-12-31.

What conditions does trial NCT04959097 study?

This clinical trial studies the following conditions: Retinoblastoma, Retinoblastoma Bilateral, Retinoblastoma Unilateral.

Who is sponsoring clinical trial NCT04959097?

This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04959097 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Retinoblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.